Zoledronic acid for adjuvant use in patients with breast cancer

References

• Jemal A, Siegel R, Xu J et al. Cancer Statistics 2010. CA Cancer J. Clin.60(5), 277–300 (2010).
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res.9, R28 (2007).
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med.356, 1670–1674 (2007).
   PubMed Web of Science ®Google Scholar
• Cuppone F, Bria E, Carlini P et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer113(2), 238–246 (2008).
   PubMedGoogle Scholar
• Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: optimizing adjuvant chemotherapy for early stage breast cancer. Nat. Rev. Clin. Oncol.7(1), 22–36 (2009).
   PubMedGoogle Scholar
• Burzykowski T, Buyse M, Piccart-Gebhart MJ et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J. Clin. Oncol.26(12), 1987–1992 (2008).
   PubMed Web of Science ®Google Scholar
• Montemurro M, Aglietta M. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocr. Relat. Cancer16(4), 1091–1102 (2009).
   PubMedGoogle Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in Her2-positive breast cancer. N. Engl. J. Med.353, 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Viani GA, Afonso SL, Stefano AJ et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer7, 153 (2007).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol.28, 509–918 (2010).
   PubMed Web of Science ®Google Scholar
• Seruga B, Ocana A, Niraula S et al. Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J. Clin. Oncol.28, 346–347 (2010).
   Google Scholar
• Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol.2, 1102–1109 (1984).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview over 63 randomized trials among 28896 women. N. Engl. J. Med.319, 1681–1692 (1988).
   PubMed Web of Science ®Google Scholar
• Lester J, Dodwell D, McCloskey E, Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat. Rev.3, 115–142 (2005).
   Google Scholar
• Greil R. The dark side of the moon – the side effects of therapy in a dynamic era of breast cancer management. Breast Care4, 144–147 (2009).
   PubMedGoogle Scholar
• Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit. Rev. Oncol. Hemat.69, 73–82 (2008).
   PubMedGoogle Scholar
• Siris ES, Chen YT, Abbott TA. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch. Intern. Med.164, 1108–1112 (2004).
   PubMed Web of Science ®Google Scholar
• Bock O, Felsenberg D. Biphosphonates in management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin. Interv. Aging3, 279–297 (2008).
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Schmidt R, Stockler M. Biphosphonates for breast cancer. Cochrane Database Syst. Rev.3, CD003474 (2005).
   Google Scholar
• Rosen LS, Gordon GH, Dugan W. Zoledronic acid is superior to pamidronate for the treatment of bone metastasis in breast carcinoma with at least one osteolytic lesion. Cancer100, 36 (2004).
   PubMed Web of Science ®Google Scholar
• Brufsky A, Bundred N, Coleman R. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist13, 503–514 (2008).
   PubMed Web of Science ®Google Scholar
• Frassoldati A, Brufsky A, Bundred N. The effect of zoledronic acid on aromatase inhibitor – associated bone loss in postmenopausal women. ESMO (2008) (Abstract 185PD).
   Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone mineral density substudy. Lancet Oncol.9, 840–849 (2008).
   PubMed Web of Science ®Google Scholar
• Hershman DL, McMahon DJ, Crew KD. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J. Clin. Oncol.26, 4739–4745 (2008).
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Halabi S, Hars V et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy. ASCO (2008) (Abstract 512).
   Google Scholar
• Brufsky A, Harker WG, Beck JT et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women. SABCS (2009) (Abstract 4083).
   Google Scholar
• Llombart A, Frassoldati A, Paija O et al. Zoledronic acid prevents aromatase inhibitor associated bone loss in postmenopausal women. Presented at: ASCO 2009 Breast Cancer Symposium. San Francisco, CA, USA, 8–10 October 2009 (Abstract 213).
   Google Scholar
• Hines SL, Mincey B, Dentchev T et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women. Breast Cancer117, 603–609 (2009).
   Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT. American Society of Clinical Oncology 2003 update on the role of biphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol.4042–4057 (2003).
   PubMedGoogle Scholar
• Ellis GK, Bone HG, Chlebowski R. Randomised trial of denosumab in patients receiving adjuvant aromatase inhibitors for non metastatic breast cancer. J. Clin. Oncol.26, 4875–4882 (2008).
   PubMed Web of Science ®Google Scholar
• Stopeck A, de Boer R, Fujiwara Y. A comparison of denusomab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases. Cancer Res.69(Suppl. 4), 490 (2009) (Abstract 422).
   Google Scholar
• Drake MT, Bart LC, Khosla S et al. Bisphosphonates: mechanisms of action and role in clinical practice. Mayo Clin. Proc.83, 1032–1045 (2008).
   PubMed Web of Science ®Google Scholar
• Brufsky AM. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist13(2), 187–195 (2008).
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther.296, 235–242 (2004).
   Google Scholar
• Kavanagh KL, Guo K, Dunford JE et al. The molecular mechanisms of nitrogen containing bisphosphonates as antiosteoporosis drugs. Proc. Natl Acad. Sci. USA103, 7829–7834 (2006).
   PubMed Web of Science ®Google Scholar
• Holstein SA, Wohlford-Lenane CL, Wiemer DF. Isoprenoid pyrophosphate analogues regulate expression of ras-related proteins. Biochemistry42(15), 4384–4391 (2003).
   PubMedGoogle Scholar
• Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer5, 405–412 (2005).
   PubMed Web of Science ®Google Scholar
• Hall A. Rho GTPases and the actin cytoskeleton. Science279(5350), 509–514 (1998).
   PubMed Web of Science ®Google Scholar
• Luckman SP, Hughes DE, Coxon FP et al. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res.13(4), 581–589 (1998).
   PubMed Web of Science ®Google Scholar
• Fleisch H. Development of bisphosphonates. Breast Cancer Res.4, 30–34 (2002).
   PubMed Web of Science ®Google Scholar
• Roelofs AJ, Thompson K, Gordon S et al. Molecular mechanisms of actions of bisphosphonates: current status. Clin. Cancer Res.12, 6222–6230 (2006).
   PubMed Web of Science ®Google Scholar
• Mönkkönen H, Lehenkari PP, Kellinsalmi M et al. A new mechanism of action for bisphosphonates: ApppI dedicated cytotoxicity of N-BPs. Bone34, S66–S67 (2006).
   Google Scholar
• Mönkkönen H, Ottewell PD, Kuokkanen J et al. Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci.81(13), 1066–1070 (2007).
   PubMedGoogle Scholar
• Aparicio A, Gardner A, Tu Y et al.In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia12, 220–229 (1998).
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer82, 1459–1468 (2000).
   PubMed Web of Science ®Google Scholar
• Tassone P, Tagliaferri P, Viscomi C et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer88, 1971–1978 (2003).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kawashima H, Onishi K et al. Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells. Anticancer Res.29, 1089–1094 (2009).
   PubMedGoogle Scholar
• Green R. Biphosphonates: preclinical Review. Oncologist9(4), 3–13 (2004).
   PubMed Web of Science ®Google Scholar
• Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest.104, 623–633 (2004).
   Google Scholar
• Croucher PI, De Hendrik R, Perry MJ et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden, and angiogenesis, and increased survival. J. Bone Miner. Res.18, 482–492 (2003).
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res.9, 2893–2897 (2003).
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Hannon RA et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol. Rep.15, 1351–1357 (2006).
   PubMedGoogle Scholar
• Hirbe AC, Roelofs AJ, Floyd DH et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone44, 908–916 (2009).
   PubMed Web of Science ®Google Scholar
• Hirbe AC, Roelofs AJ, Caraglia M et al. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin. Pharmacother.11, 141–154 (2010).
   PubMedGoogle Scholar
• Senaratne SG, Masni JL, Colston KW. The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells. Br. J. Cancer86, 1479–1486 (2002).
   PubMed Web of Science ®Google Scholar
• Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res.15, 2211–2221 (2000).
   PubMed Web of Science ®Google Scholar
• Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys.373, 231–241 (2000).
   PubMed Web of Science ®Google Scholar
• Benford HL, McGowan NW, Helfrich MH et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone28, 465–473 (2001).
   PubMed Web of Science ®Google Scholar
• Daubine F, Le Gall C, Gasser J et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J. Natl Cancer Inst.99, 322–330 (2007).
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer84, 1126–1134 (2001).
   PubMed Web of Science ®Google Scholar
• Vogt U, Wassmann K, Bosse U et al. Enhancement of breast tumor growth inhibition (BTGI) in vitro through combination of CMF, epirubicin/cyclophosphamide (EC), epirubicin/paclitaxel (ET) and epirubicin/docetaxel (EDoc) with ibandronate (IB) or zoledronic acid (ZOL). Proc. Am. Soc. Clin. Oncol.22, 55 (2003).
   Google Scholar
• Jagdev SP, Croucher P, Coleman RE et al. Zoledronate induces apoptosis of breast cancer cells in vitro-evidence for additive and synergistic effects with taxol and tamoxifen. Proc. Am. Soc. Clin. Oncol.19, 664a (2000).
   Google Scholar
• Winter MC, Holen I, Coleman RE et al. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev.34, 453–475 (2008).
   PubMed Web of Science ®Google Scholar
• Neville-Webbe HL, Coleman RE, Holen I et al. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br. J. Cancer102, 1010–1017 (2010).
   PubMed Web of Science ®Google Scholar
• Ottewell PD, Deux B, Mönkkönen H et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin. Cancer Res.14, 4658 (2008).
   PubMed Web of Science ®Google Scholar
• Wakchoure S, Merell MA, Aldrich W et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin. Cancer Res.12, 862–868 (2006).
   Google Scholar
• Matsumoto S, Kimura S, Segawa H et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer47, 31–39 (2005).
   PubMed Web of Science ®Google Scholar
• Li YY, Chang JW, Chou WC et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer59(2), 180–191 (2008).
   PubMed Web of Science ®Google Scholar
• Nobuyuki H, Hiraga T, Williams PJ et al. The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J. Bone Miner. Res.16(Suppl. 1), S191 (2001).
   Google Scholar
• Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on cancer. Calcif. Tissue Int.73, 315–318 (2003).
   PubMedGoogle Scholar
• Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat. Rev.34, 19–21 (2008).
   Web of Science ®Google Scholar
• Coleman R. On the horizon: can bisphosphonates prevent bone metastases? Breast16, 21–27 (2007).
   Google Scholar
• Bundred N, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. Cancer112, 1001–1010 (2008).
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med.360(22), 2367 (2009).
   Google Scholar
• Coleman R, Winter MC, Cameron D et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br. J. Cancer102, 1099–1105 (2010).
   PubMed Web of Science ®Google Scholar
• Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int.41, 326–331 (1987).
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J et al. Stimulation of γδ T cells by amino-bisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood96, 384–392 (2000).
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Wilhelm M. γδ T cell stimulation by pamidronate. N. Engl. J. Med.340, 737–738 (1999).
   PubMed Web of Science ®Google Scholar
• Born WK, Reardon CL, O’Brien RL. The function of γδ T cells in innate immunity. Curr. Opin. Immunol.18, 31–38 (2006).
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kistowska M, Angman L et al. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med.197, 163–168 (2003).
   PubMed Web of Science ®Google Scholar
• Casetti R, Martino A. The plasticity of γδ T cells: innate immunity, antigen presentation and new immunotherapy. Cell. Mol. Immunol.5(3), 161–170 (2008).
   PubMed Web of Science ®Google Scholar
• Galluzzo S, Santini D, Vincenzi B et al. Immunmodulating role of bisphosphonates on human γ δ T cells: an intringuing and promising aspect of their antitumor activity. Expert Opin. Ther. Targets11, 941–954 (2007).
   PubMed Web of Science ®Google Scholar
• Caccamo N, Meraviglia S, Scarpa F et al. Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no more. Expert Opin. Biol. Ther.8(7), 875–883 (2008).
   PubMed Web of Science ®Google Scholar
• Sato K, Kimura S, Yokota A et al. Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer116(1), 94–99 (2005).
   PubMed Web of Science ®Google Scholar
• Hayday AC. γδ cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol.18, 975–1026 (2000).
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Kunzmann V, Eckstein S et al. γδ T cells for immune therapy of patients with lymphoid malignancies. Blood102, 200–206 (2003).
   PubMed Web of Science ®Google Scholar
• Dieli F, Vermijlen D, Fulfaro F et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res.67(15), 7450–7457 (2007).
   PubMed Web of Science ®Google Scholar
• Meraviglia S, Eberl M, Vermijlen D et al.In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exper. Immunol.161(2), 290–297 (2010).
   PubMedGoogle Scholar
• Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomised, Phase 2 trial. Lancet Oncol.11, 421–429 (2010).
   PubMed Web of Science ®Google Scholar
• Hirbe A, Morgan FA, Uluckan O et al. Skeletal complications of breast cancer therapies. Clin. Cancer Res.12, 6309–6314 (2006).
   Web of Science ®Google Scholar
• Käkönen SM, Mundy G. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer97, 834–839 (2003).
   PubMed Web of Science ®Google Scholar
• Braun S, Pantel K, Müller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N. Engl. J. Med.342, 525–533 (2000).
   PubMed Web of Science ®Google Scholar
• Wiedswang G, Borgen E, Karesen R et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J. Clin. Oncol.21, 3469–3478 (2003).
   PubMed Web of Science ®Google Scholar
• Rack B, Schindlbeck C, Strobl B et al. Efficacy of zoledronate in treating persisting isolated tumour cells in bone marrow in patients with breast cancer. Dtsc. Med. Wochenschr.133, 285–289 (2008).
   PubMedGoogle Scholar
• Lin A, Park J, Melisko M et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow. Cancer Res.68, (2007) (Abstract 510).
   Google Scholar
• Greenberg S, Park JW, Melisko ME et al. Effect of adjuvant zoledronic acid on disseminated tumor cells in the bone marrow of women with early stage breast cancer: updated results. ASCO (2010) (Abstract 1002).
   Google Scholar
• Green, JR. Moiler, K. Jaeggi, KA. Preclinical pharmacology of CGP 42’ 446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res.9, 745–751 (1994).
   PubMed Web of Science ®Google Scholar
• Green R. Zoledronic acid: pharmacologic profile of a potent bisphosphonate. Organometallic Chem.690, 2439–2448 (2005).
   Google Scholar
• Russel RG. Bisphosphonates: from bench to bedside. Ann. NY Acad. Sci.1068, 367–401 (2006).
   PubMed Web of Science ®Google Scholar
• Glatt M. The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography. Eur. Cells Materials296, 238–242 (2000).
   Google Scholar
• Body JJ, Lortholary A, Romieu G et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. Bone Miner. Res.14, 1557–1561 (1999).
   PubMed Web of Science ®Google Scholar
• Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol.19, 558–567 (2001).
   PubMed Web of Science ®Google Scholar
• Saad F, Donald M, Gleason R et al. A randomized placebo controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J. Natl Cancer Inst.94(19), 1458–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst.96, 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol.21, 3150–3157 (2003).
   PubMed Web of Science ®Google Scholar
• Rosen L, Gordon D, Tchekmediyan S et al. Long-term zoledronic acid therapy is effective and safe for reducing the risk of skeletal complications in patients with non-small cell lung cancer (NSCLC) and bone metastases. Bone34(1), S89 (2004) (Abstract 73).
   Google Scholar
• Lipton A, Zheng M, Seaman J et al. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer98, 962–969 (2004).
   Google Scholar
• Lipton A, Seaman J, Zheng M et al. Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Bone24(1), S62 (2004) (Abstract 28).
   Google Scholar
• Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer98, 1735–1744 (2003).
   PubMed Web of Science ®Google Scholar
• Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J. Clin. Oncol.23, 3314–3321 (2005).
   PubMed Web of Science ®Google Scholar
• Ibrahim A, Scher N, Williams G et al. Approval summary for zoledronic acid for treatment of multiple myeloma and bone metastases. Clin. Cancer Res.9, 2394 (2003).
   PubMed Web of Science ®Google Scholar
• Chen T, Berenson J, Vescio R et al. Pharmacokinetiks and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. Clin. Pharmacol.42, 1228–1236 (2002).
   Google Scholar
• Skerjanec A, Berenson J, Major P et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. Clin. Pharmacol.43, 154–162 (2003).
   Google Scholar
• Berenson J, Hirschberg R. Safety and Convenience of a 15 minute infusion of zoledronic acid. Oncologist9(3), 319–329 (2004).
   PubMed Web of Science ®Google Scholar
• Zometa ®, Summary of product characteristics. Novartis Pharma AG, Switzerland (2010).
   Google Scholar
• Chang JT, Green L, Beitz J et al. Renal failure with the use of zoledronic acid. N. Engl. J. Med.17, 1676–1679 (2003).
   Google Scholar
• Smetana S, Michlin A, Rosenman E et al. Pamidronate induced nephrotoxic tubular necrosis – a case report. Clin. Nephrol.61(1), 63–67 (2003).
   Google Scholar
• Wakchoure S, Merell MA, Aldrich W et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin. Cancer Res.12, 862–868 (2006).
   Google Scholar
• Zaghloul MS, Boutrus R, El-Hosieny H. A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients. J. Clin. Oncol.26 (2008) (Abstract 5033).
   PubMedGoogle Scholar
• Aviles A, Nambo MJ, Neri N. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med. Oncol.24, 227–230 (2007).
   PubMed Web of Science ®Google Scholar
• Eidtmann H, Bundred NJ, de Boer R et al. Efficacy of zolerdronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann. Oncol.10, 1093 (2010).
   Google Scholar
• Coleman RE, Thorpe HC, Cameron D et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The Azure Trial (BIG 01/04). Cancer Res.70(Suppl. 4), S4–S5 (2010).
   PubMedGoogle Scholar
• Mauri D, Valachis A, Polyzos NP et al. Does adjuvant bisphosphonate in adjuvant breast cancer modify the natural course of the disease ? A metaanalysis of randomized controlled trials. J. Natl Compr. Cancer Net.8, 279–286 (2010).
   PubMed Web of Science ®Google Scholar
• Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer91, 1191–1200 (2001).
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R et al. HORIZON Pivotal Fracture Trial. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med.356(18), 1809–1822 (2007).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Schwartz AV, Black DM et al. Alendronate and atrial fibrillation (letter). N. Engl. J. Med.356(18), 1895–1896 (2007).
   PubMed Web of Science ®Google Scholar
• Heckbert SR, Li G, Cummings SR et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med.168(8), 826–831 (2008).
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Christensen S, Mehnert F et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case–control study. BMJ336(7648), 813–816 (2008).
   PubMed Web of Science ®Google Scholar
• Woo SB, Hellstein JW, Kalmar JR et al. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws published correction appears in Ann. Intern. Med.145(3), 235 (2006).
   Google Scholar
• Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica91(7), 968–971 (2006).
   PubMed Web of Science ®Google Scholar
• Corso A, Varettoni M, Zappasodi P et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia21(7), 1545–1548 (2007).
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res.22(10), 1479–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Gralow JR, Biermann S, Farooki A et al. NCCN Task Force Report: bone health in cancer care. J. Nat. Compr. Cancer Network7(3), S1–31 (2009).
   PubMedGoogle Scholar
• Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg.63(11), 1567–1575 (2005).
   PubMed Web of Science ®Google Scholar
• Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol.23(34), 8580–8587 (2005).
   PubMed Web of Science ®Google Scholar
• Lenart BA, Lorich DG, Lane JM et al. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N. Engl. J. Med.358, 1304–1306 (2008).
   PubMed Web of Science ®Google Scholar
• Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J. Bone Joint Surg.91(11), 2556–2561 (2009).
   PubMed Web of Science ®Google Scholar
• Black DM, Kelly MP, Genant HK et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med.362, 1761–1771 (2010).
   PubMed Web of Science ®Google Scholar
• Lipton A. Should biphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res. Treat.10, 935–937 (2010).
   Google Scholar
• Fox R. Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea? Curr. Oncol. Rep.12, 1–3 (2010).
   PubMedGoogle Scholar
• Body JJ, Diel IJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer90, 1133–1137 (2004).
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitser MR et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol.14, 1399–1405 (2003).
   PubMed Web of Science ®Google Scholar